



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 7, 2020

Anthony Fernando
Chief Executive Officer
Transenterix, Inc.
635 Davis Drive, Suite 300
Morrisville, NC 27560

Re: Transenterix, Inc.
Registration Statement on Form S-3
Filed January 31, 2020
File No. 333-236200

Dear Mr. Fernando:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Paul Fischer at 202-551-3415 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Mary Mullany, Esq.